Opinion
Video
Dr. Huelster on the use of ctDNA in upper tract urothelial carcinoma
Author(s):
“[Although] not yet ready for prime time, ctDNA is being investigated as a very promising non-invasive plasma biomarker of invasive or advanced-stage upper tract urothelial carcinoma,” says Heather L. Huelster, MD.
In this video, Heather L. Huelster, MD, shares the take-home message from the recent European Urology study “Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non–organ-confined Upper Tract Urothelial Carcinoma.” Huelster is an assistant professor of urology at Indiana University School of Medicine in Indianapolis.
Transcription:
What is the take-home message for the practicing urologist?
[Although] not yet ready for prime time, ctDNA is being investigated as a very promising non-invasive plasma biomarker of invasive or advanced-stage upper tract urothelial carcinoma. It has the potential to help us overcome some of these current obstacles in clinical staging unique to this disease space, and may help us identify the appropriate patients for referral to medical oncology and consideration of neoadjuvant chemotherapy prior to planning for radical nephroureterectomy.
This transcription was edited for clarity.
